What is LATE dementia and how is it different from Alzheimer's?

LATE, or Limbic-predominant age-related TDP-43 encephalopathy, is a form of dementia that can mimic Alzheimer's symptoms but is biologically distinct, involving TDP-43 protein accumulation rather than amyloid plaques.

How common is LATE dementia according to recent guidelines?

Recent guidelines estimate LATE affects about a third of people 85 and older and 10 percent of those 65 and older.

Is there a clinical trial for LATE dementia at the University of Kentucky?

Yes, the University of Kentucky is conducting the first clinical trial testing a treatment for LATE, involving a drug called nicorandil.

Home / Health / New Dementia: LATE Changes Diagnosis Landscape

New Dementia: LATE Changes Diagnosis Landscape

29 Nov, 2025

•

Summary

LATE dementia affects a third of people 85 and older.
It can mimic Alzheimer's but is usually less severe.
A trial for LATE treatment is underway at the University of Kentucky.

New Dementia: LATE Changes Diagnosis Landscape

A recently identified dementia, known as LATE, is significantly altering perceptions of cognitive decline and improving diagnostic capabilities for patients. Current guidelines suggest LATE impacts about 10 percent of individuals aged 65 and older, and approximately one-third of those 85 and above. Experts note that some patients previously diagnosed with Alzheimer's may actually have LATE. This condition, while often less severe than Alzheimer's individually, can drastically worsen outcomes when it co-occurs with Alzheimer's pathology, leading to more rapid symptom progression and a more severe prognosis.

Biologically distinct from Alzheimer's, which involves amyloid and tau proteins, LATE is characterized by the abnormal accumulation of TDP-43 protein. Diagnosis typically involves brain imaging and ruling out Alzheimer's pathology. Patients with pure LATE may not qualify for newly approved Alzheimer's drugs, which target amyloid. The interaction between LATE and Alzheimer's also complicates treatment decisions for patients with both conditions.